Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

vTv Therapeutics to Present at Two Investor Conferences in March

VTVT

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe, President and CEO and Dr. Larry Altstiel, EVP, Chief Medical Officer, will present a corporate overview at two investor conferences in March.

Presentation Details:

Cowen and Company 36th Annual Health Care Conference

  • Location: Boston, MA
  • Presentation Date: Tuesday, March 8, 2016
  • Presentation Time: 9:20am ET

28th Annual ROTH Conference

  • Location: Dana Point, CA
  • Presentation Date: Tuesday, March 15, 2016
  • Presentation Time: 5:30pm PT

Live webcasts of the presentations can be accessed on the News & Events section of the website. The webcasts will be archived for 30 days following the presentations on the Company’s website at www.vtvtherapeutics.com.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Investors
The Trout Group
Adam Krop, 646-378-2963
akrop@troutgroup.com
or
Media
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today